A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurren...

• Country None
• organs None
• Specialty None

A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurren...

• Country None
• organs None
• Specialty None

A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses To determine the effect of teriflunomide in reducing the frequency of relapses in subjects with relapsing multiple sclerosis.

• Country None
• organs None
• Specialty None

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 μg bid) for 4 weeks, or in an 80 μg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids To investigate the efficacy, compared to placebo, of ciclesonide at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM r...

• Country None
• organs None
• Specialty None